The aspiration of this study was to develop a high target potency drug to aggrandize the normal wound healing progresses through inflammatory, proliferative and remodeling phases in response to tissue injury. One of the essential components of the extracellular matrix is collagen, which serves as indispensable for controlling the various stages of wound healing. The Eichhornia crassipes extract exhibited significant free radical scavenging activities with 72.1% and 80% inhibition in DPPH and ABTS assays at 0.1 mg/ml, respectively. Notably, it showed 80.2% inhibition of α-amylase and 87.3% of α-glucosidase, indicating strong antidiabetic potential. In anti-inflammatory assays, the extract demonstrated effective protection against RBC lysis, highlighting its membrane-stabilizing properties. Antibacterial tests revealed notable activity against various pathogens, with inhibition zones up to 15 mm. Cytotoxicity assays indicated variable effects on Vero cell morphology, while wound healing studies showed enhanced cell migration and scratch closure rates. The results were then validated by the use of Molecular docking, oral bioavailability parameters (TOPKAT), ADMET risk screening and in-silico pharmacokinetics and pharmacodynamics analysis which identified phytochemicals indicated promising drug-like properties.